However, previously reported del-LMP1 variant and EBNA2 expressions or a possible LMP2 might also be involved in these tumors, suggesting type II or more likely type III latency similar to post-transplant lymphoproliferative disorders (1,13). This evidence concerns the gene PDLIM7 and lymphoproliferative syndrome.